Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 110923303 | 11092330 | 3 | F | 20160908 | 20150506 | 20160913 | EXP | IT-ROCHE-1572353 | ROCHE | , CREMOLINI C, LOUPAKIS F, BARBARA C, DARGENIO F, MIRAGLIO E, MASI G, SALVATORE L, MARCUCCI L, ANTONUZZO L, CHIARA S, BANZI C, SCHIRRIPA M, AMOROSO D, BONETTI A, MARTIGNETTI A, PARIS M, BONI L, TOMCIKOVA D AND FALCONE A LACTATE DEHYDROGENASE (LDH) LEVELS TO PREDICT BENEFIT FROM THE CONTINUATION OF BEVACIZUMAB (BEV) BEYOND PROGRESSION IN METASTATIC COLORECTAL CANCER (MCRC): SUBGROUP ANALYSIS OF THE RANDOMIZED BEBYP STUDY [ABS NO:E15127]. JOURNAL OF CLINICAL ONCOLOGY 2016 MAY;34 (SUP15):-. | 0.00 | Y | 0.00000 | 20160914 | MD | IT | IT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 110923303 | 11092330 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Unknown | U | 125085 | ||||||||||
| 110923303 | 11092330 | 2 | SS | FOLINIC ACID | LEUCOVORIN | 1 | Unknown | U | 0 | ||||||||||
| 110923303 | 11092330 | 3 | SS | FLUOROURACIL. | FLUOROURACIL | 1 | Unknown | U | 0 | ||||||||||
| 110923303 | 11092330 | 4 | SS | OXALIPLATIN. | OXALIPLATIN | 1 | Unknown | U | 0 | ||||||||||
| 110923303 | 11092330 | 5 | SS | IRINOTECAN | IRINOTECAN | 1 | Unknown | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 110923303 | 11092330 | 1 | Colorectal cancer metastatic |
| 110923303 | 11092330 | 2 | Colorectal cancer metastatic |
| 110923303 | 11092330 | 3 | Colorectal cancer metastatic |
| 110923303 | 11092330 | 4 | Colorectal cancer metastatic |
| 110923303 | 11092330 | 5 | Colorectal cancer metastatic |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 110923303 | 11092330 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 110923303 | 11092330 | Arterial thrombosis | |
| 110923303 | 11092330 | Diarrhoea | |
| 110923303 | 11092330 | Febrile neutropenia | |
| 110923303 | 11092330 | Haematuria | |
| 110923303 | 11092330 | Hypertension | |
| 110923303 | 11092330 | Neurotoxicity | |
| 110923303 | 11092330 | Neutropenia | |
| 110923303 | 11092330 | Stomatitis | |
| 110923303 | 11092330 | Thrombocytopenia | |
| 110923303 | 11092330 | Venous thrombosis | |
| 110923303 | 11092330 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |